These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23681955)

  • 1. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
    Stamp LK; O'Donnell JL; Frampton C; Drake JM; Zhang M; Chapman PT
    Arthritis Rheum; 2013 Jun; 65(6):1636-42. PubMed ID: 23681955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
    Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
    Dalbeth N; Billington K; Doyle A; Frampton C; Tan P; Aati O; Allan J; Drake J; Horne A; Stamp LK
    Arthritis Rheumatol; 2019 Oct; 71(10):1739-1746. PubMed ID: 31081595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two plasma urate assays in patients receiving vitamin C supplementation.
    Sies CW; Florkowski CM; Frampton CM; O'Donnell JL; Chapman PT; Stamp LK
    Pathology; 2014 Jun; 46(4):333-5. PubMed ID: 24798153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
    Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
    Pui K; Gow PJ; Dalbeth N
    J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial.
    Huang HY; Appel LJ; Choi MJ; Gelber AC; Charleston J; Norkus EP; Miller ER
    Arthritis Rheum; 2005 Jun; 52(6):1843-7. PubMed ID: 15934094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.